KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Tax Provisions (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Tax Provisions for 8 consecutive years, with -$382000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 77.6% to -$382000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.4 million through Dec 2025, down 262.4% year-over-year, with the annual reading at -$5.4 million for FY2025, 261.37% down from the prior year.
  • Tax Provisions hit -$382000.0 in Q4 2025 for Castle Biosciences, down from $115000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $6.0 million in Q3 2024 to a low of -$4.7 million in Q2 2025.
  • Historically, Tax Provisions has averaged -$323823.5 across 5 years, with a median of $14000.0 in 2023.
  • Biggest five-year swings in Tax Provisions: plummeted 39240.0% in 2022 and later soared 18690.62% in 2024.
  • Year by year, Tax Provisions stood at -$1.8 million in 2021, then skyrocketed by 103.21% to $57000.0 in 2022, then plummeted by 31.58% to $39000.0 in 2023, then plummeted by 4471.79% to -$1.7 million in 2024, then soared by 77.6% to -$382000.0 in 2025.
  • Business Quant data shows Tax Provisions for CSTL at -$382000.0 in Q4 2025, $115000.0 in Q3 2025, and -$4.7 million in Q2 2025.